Antidiabetic Activity Test of Ethyl Acetate Fraction of Bengkal Leaves (Nauclea orientalis L.) on Male White Mice

Lailan Azizah; Andy Brata

doi:10.55927/fjst.v5i1.399

Authors

Lailan Azizah Poltekkes Kemenkes Jambi
Andy Brata Poltekkes Kemenkes Jambi

DOI:

https://doi.org/10.55927/fjst.v5i1.399

Keywords:

Antidiabetic Activity, Bengkal Leaves, Ethyl Acetate Fraction, Male White Mice, Nauclea orientalis L

Abstract

Diabetes mellitus remains a major global health problem, driving the search for safe and effective natural antidiabetic agents. This quasi-experimental study evaluates the antidiabetic activity of the ethyl acetate fraction of bengkal leaves (Nauclea orientalis L.) and determines the optimal dose in alloxan-induced male mice. Using a completely randomized design, 30 mice were divided into six groups: negative control, positive control (glibenclamide 0.65 mg/kgBW), and treatment groups receiving 150, 300, 450, and 600 mg/kgBW of the ethyl acetate fraction. Blood glucose levels were measured on days 1, 3, and 7 and analyzed using ANOVA and Duncan’s post hoc test. The results show a significant reduction in blood glucose levels (p < 0.001), with the 450 mg/kgBW dose being the most effective, producing a 49.53% decrease on day 7, comparable to the positive control. Higher doses showed lower effectiveness. The study concludes that the ethyl acetate fraction of bengkal leaves has strong antidiabetic activity and potential for development as a phytopharmaceutical candidate for diabetes management.

References

Abubakar, A. R., Haque, M., & Afolayan, A. J. (2022). Antidiabetic and antioxidant activities of Nauclea species: Evidence from experimental studies. Journal of Ethnopharmacology, 294, 115332. https://doi.org/10.1016/j.jep.2022.115332

Al-Ishaq, R. K., Abotaleb, M., Kubatka, P., Kajo, K., & Büsselberg, D. (2022). Flavonoids and their anti-diabetic effects: Cellular mechanisms and clinical perspectives. Biomedicine & Pharmacotherapy, 149, 112830. https://doi.org/10.1016/j.biopha.2022.112830

Ayepola, O. R., Chegou, N. N., & Oguntibeju, O. O. (2022). Evaluation of antidiabetic potential of plant-derived compounds in animal models. Journal of Diabetes Research, 2022, 1–11. https://doi.org/10.1155/2022/9812045

Azwanida, N. N. (2021). A review on the extraction methods use in medicinal plants, principle, strength and limitation. Medicinal & Aromatic Plants, 10(2), 1–6. https://doi.org/10.35248/2167-0412.21.10.388

Calabrese, E. J., & Mattson, M. P. (2021). Hormesis provides a generalized quantitative estimate of biological plasticity. Journal of Cell Communication and Signaling, 15(1), 1–10. https://doi.org/10.1007/s12079-020-00618-2

Charan, J., & Kantharia, N. D. (2021). How to calculate sample size in animal studies? Journal of Pharmacology & Pharmacotherapeutics, 12(1), 1–6. https://doi.org/10.4103/jpp.jpp_21_20

Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., & Del Prato, S. (2022). Management of hyperglycemia in type 2 diabetes. Diabetes Care, 45(11), 2753–2786. https://doi.org/10.2337/dci22-0034

DeFronzo, R. A., Norton, L., & Abdul-Ghani, M. (2021). Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nature Reviews Nephrology, 17(1), 11–26. https://doi.org/10.1038/s41581-020-00350-8

Dirir, A. M., Daou, M., Yousef, A. F., & Yousef, L. F. (2022). Alpha-glucosidase inhibitors from plants as potential candidates for type 2 diabetes. Phytochemistry Reviews, 21(4), 1049–1079. https://doi.org/10.1007/s11101-021-09773-1

Eddouks, M., Chattopadhyay, D., & Zeggwagh, N. A. (2021). Animal models as tools to investigate antidiabetic and anti-inflammatory plants. Evidence-Based Complementary and Alternative Medicine, 2021, 1–14. https://doi.org/10.1155/2021/6682021

Field, A. (2020). Discovering statistics using IBM SPSS statistics (5th ed.). SAGE Publications. https://doi.org/10.4135/9781529716594

Gidado, A., Ameh, D. A., & Ibrahim, S. (2021). Hypoglycaemic activity of Nauclea latifolia in experimental animals. African Journal of Traditional, Complementary and Alternative Medicines, 18(1), 1–9. https://doi.org/10.4314/ajtcam.v18i1.1

Harris, A. D., McGregor, J. C., & Perencevich, E. N. (2020). The use and interpretation of quasi-experimental studies in medical research. Clinical Infectious Diseases, 70(2), 202–207. https://doi.org/10.1093/cid/ciz400

Kashtoh, H., & Baek, K. H. (2022). Phytoconstituent alpha-glucosidase inhibitors for type 2 diabetes treatment. Plants, 11(20), 2722. https://doi.org/10.3390/plants11202722

Liu, Y., Wang, H., & Chen, X. (2024). Time-dependent pharmacological evaluation of herbal antidiabetic agents in experimental models. Journal of Diabetes Research, 2024, 1–12. https://doi.org/10.1155/2024/8812947

Ngau, T. H., Phuong, N. M., & Bien, L. D. (2024). Antihyperglycemic potential of Nauclea orientalis. HUIT Journal of Science, 24(5), 19–32. https://doi.org/10.62985/j.huit_ojs.vol24.no5.128

OECD. (2022). Guidance document on the validation of in vitro methods. OECD Publishing. https://doi.org/10.1787/9789264304781-en

Pan, G., Lu, Y., Wei, Z., Li, Y., & Pan, X. (2024). Screening of alpha-glucosidase inhibitors in vitro and in vivo. Heliyon, 10(18), e37467. https://doi.org/10.1016/j.heliyon.2024.e37467

Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., & Dirnagl, U. (2020). The ARRIVE guidelines 2.0. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410

Petersmann, A., Müller-Wieland, D., Müller, U. A., Landgraf, R., Nauck, M., & Freckmann, G. (2020). Definition, classification and diagnosis of diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes, 128(S01), S1–S15. https://doi.org/10.1055/a-1018-9078

Radenković, M., Stojanović, M., & Prostran, M. (2021). Experimental diabetes induced by alloxan and streptozotocin: The current state of the art. Journal of Pharmacological and Toxicological Methods, 111, 106889. https://doi.org/10.1016/j.vascn.2021.106889

Rao, M. U., Sreenivasulu, M., Chengaiah, B., Reddy, K. J., & Chetty, C. M. (2022). Herbal medicines for diabetes mellitus: A review. International Journal of Phytopharmacology, 13(2), 89–102. https://doi.org/10.31254/phyto.2022.13203

Saeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., & Unwin, N. (2021). Global and regional diabetes prevalence estimates. Diabetes Research and Clinical Practice, 173, 108821. https://doi.org/10.1016/j.diabres.2020.108821

Silva, F. M., Souza, L. F., & Pereira, M. G. (2024). Dose–response assessment of plant-based antidiabetic agents in experimental models. Pharmaceutical Biology, 62(1), 245–256. https://doi.org/10.1080/13880209.2023.2289457

Zhang, Y., Li, X., & Zhao, W. (2023). Multi-target mechanisms of plant secondary metabolites in diabetes management. Frontiers in Pharmacology, 14, 1187426. https://doi.org/10.3389/fphar.2023.1187426

Zhang, Y., Liu, J., Wang, X., & Chen, L. (2023). Bioactivity-guided fractionation of medicinal plants for antidiabetic drug discovery. Frontiers in Pharmacology, 14, 1189456. https://doi.org/10.3389/fphar.2023.1189456

Zheng, Y., Ley, S. H., & Hu, F. B. (2021). Global aetiology and epidemiology of type 2 diabetes mellitus. Nature Reviews Endocrinology, 17(2), 88–98. https://doi.org/10.1038/s41574-020-00411-0